RiboBio completes $40 million in Series E financing

Ribo Bio is an innovative drug research and development enterprise dedicated to the development of RNA interference technology, and a major pioneer of small nucleic acid technology and small nucleic acid pharmaceuticals in China. Recently, RiboBio completed a $40 million Series E financing. This round of financing was mainly completed by existing shareholders such as Panlin Capital and Sany Innovation Investment, as well as new institutional and individual investors in this round. The funds raised in this round will continue to support RiboBio’s multi-species global development at different R&D stages, as well as the iteration of existing small nucleic acid technology, especially the research on non-liver targeted delivery technology.

This article is reproduced from: https://www.itjuzi.com/investevent/13415683
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.